International Dermatology Outcome Measures

What International Dermatology Outcome Measures does

International Dermatology Outcome Measures (IDEOM) is a 501(c)(3) nonprofit organization founded in 2013 and headquartered in Roseville, California. Its stated mission is to establish patient-centric outcome measures to enhance research and treatment of dermatological conditions. The organization operates as a multi-stakeholder collaboration platform, bringing together patients, healthcare providers, pharmaceutical and biotech industry partners, patient advocacy groups, non-profits, methodologists, health economists, and the FDA. Its core products are 11 disease-specific workgroups (Acne, Actinic Keratosis, Alopecia Areata, Connective Tissue Diseases, Cutaneous T-Cell Lymphoma, Hidradenitis Suppurativa, Itch, Psoriatic Disease, Psoriasis, Psoriatic Arthritis, and Vitiligo) that produce consensus-based outcome measures, core domain sets, and assessment tools such as the sPGAxBSA composite for psoriasis and standardized severity expressions for vitiligo. These outputs are disseminated via peer-reviewed publications, the IDEOM website, and an annual scientific meeting, with the 13th Annual Meeting scheduled for June 19-20, 2026 in Washington, DC. The organization has no software product and no disclosed revenue; its activities are funded through sponsorships and donations. Its collaboration network spans 21 countries across six continents, and its leadership includes President Dr. Alice Gottlieb and workgroup chairs at institutions including UT Southwestern and UCLA.

Name

International Dermatology Outcome Measures

Legal name

International Dermatology Outcome Measures

Website

https://dermoutcomes.org

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

IDEOM is a 501(c)(3) nonprofit that convenes patients, providers, industry, and the FDA to develop standardized, patient-centric outcome measures for dermatology across 11 disease workgroups in 21 countries.

Ownership category

akta.pro rank

Product category

Dermatology Clinical Research Standards

SIC

Services-Health Services (8000)

akta.pro primary industry

General & Medical Dermatology (HLAKACAA)

akta.pro secondary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

• Dermatology outcome measures
• Clinical outcome research
• Patient-reported outcomes
• Dermatology consensus standards
• Clinical trial endpoints

Headquarters

HQ city

Roseville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Marketing channels1 record

Core offering

IDEOM develops standardized, patient-centric outcome measures for dermatological conditions by coordinating multi-stakeholder collaboration among patients, healthcare providers, industry, patient advocacy groups, methodologists, health economists, and the FDA. It operates eleven disease-specific workgroups, publishes consensus outcome measures and core domain sets, and hosts annual scientific meetings to advance dermatology research and clinical practice.

Product overview

IDEOM (International Dermatology Outcome Measures) is a 501(c)(3) nonprofit organization that serves as a collaboration platform bringing together diverse stakeholders including Patients, Industry, Patient Advocacy Groups, Healthcare Providers, Non-Profits, Methodologists, Health Economists, and the FDA. The organization operates specialized Workgroups focused on specific dermatological conditions (Acne, Actinic Keratosis, Alopecia Areata, Connective Tissue Diseases, Cutaneous T-Cell Lymphoma, Hidradenitis Suppurativa, Itch, Psoriatic Disease, Psoriasis, Psoriatic Arthritis, and Vitiligo) to develop standardized, patient-centric outcome measures for dermatological research and clinical practice. IDEOM produces publications including outcome measure consensus documents, core domain sets, and assessment tools, and hosts annual scientific meetings. The organization does not offer a software product but rather serves as a coordinating body that produces measurement standards and guidelines for the dermatology research community.

Differentiator

Problem solved

Functional benefit

Products and services

• IDEOM Collaboration Platform Multi-stakeholder collaboration platform that brings together patients, industry, patient advocacy groups, healthcare providers, non-profits, methodologists, health economists, and the FDA to establish patient-centric outcomes for dermatological research and treatment.
• Workgroups Program Specialized working groups focused on 11 specific dermatological conditions (Acne, Actinic Keratosis, Alopecia Areata, Connective Tissue Diseases, Cutaneous T-Cell Lymphoma, Hidradenitis Suppurativa, Itch, Psoriatic Disease, Psoriasis, Psoriatic Arthritis, and Vitiligo) that develop consensus-based outcome measures for each condition.
• Annual Scientific Meetings

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• OMERACT (Outcome Measures in Rheumatology): OMERACT is the prototypical international consensus initiative for outcome measures in rheumatology; it pioneered the model that IDEOM has adapted for dermatology and shares the same multi-stakeholder, Delphi-based methodology.
• HOME (Harmonising Outcome Measures for Eczema): HOME is a global initiative that develops core outcome sets for atopic eczema — directly analogous to IDEOM's mission of producing standardized, consensus-based outcome measures for specific dermatology conditions.
• ICHOM (International Consortium for Health Outcomes Measurement): ICHOM develops standardized outcome sets for medical conditions globally using multi-stakeholder consensus — closely paralleling IDEOM's methodology and mission across multiple specialties.
• COMET Initiative (Core Outcome Measures in Effectiveness Trials): COMET promotes the development and application of core outcome sets across medical specialties; IDEOM effectively functions as a dermatology-specific instantiation of the COMET framework.

Others

• CDISC (Clinical Data Interchange Standards Consortium): CDISC develops data standards for clinical research that complement outcome-measure standards like those produced by IDEOM; both sit in the ecosystem enabling regulatory-grade dermatology trials.
• GRADE Working Group: GRADE develops widely adopted frameworks for evidence assessment and guideline development — methodology that underpins how consensus outcome measures like IDEOM's are evaluated and adopted.

Emerging players

• C-Path (Critical Path Institute): C-Path convenes consortia to develop drug-development tools and regulatory-grade data standards across multiple diseases, overlapping with IDEOM's work on clinical-trial endpoint validation in dermatology.

Broad incumbents

• ISPOR (International Society for Pharmacoeconomics and Outcomes Research): ISPOR is a broader professional society advancing health-outcomes research and patient-reported outcomes methodology — overlapping with IDEOM's methodologist and health-economist stakeholder communities.
• American Academy of Dermatology (AAD): The AAD is the largest U.S. dermatology professional society and awards body; IDEOM's leadership has deep AAD ties, and AAD-adjacent guidelines intersect with IDEOM's outcome-measure work.

Regional players

• European Academy of Dermatology and Venereology (EADV): EADV is the principal European dermatology professional society; it operates in overlapping condition areas and convenes similar European dermatology outcome-measure initiatives.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/international-dermatology-outcome-members-ideom-

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about International Dermatology Outcome Measures